Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?

Eduardo Ramacciotti; Leandro B Agati; Roberto Augusto Caffaro; Giuliano G Volpiani; Renato D Lopes; Anthony J Comerota; Jawed Fareed

doi:10.1177/1076029619856433

Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?

Clin Appl Thromb Hemost. 2019 Jan-Dec:25:1076029619856433. doi: 10.1177/1076029619856433.

Authors

Eduardo Ramacciotti^{1

2

3}, Leandro B Agati¹, Roberto Augusto Caffaro², Giuliano G Volpiani^{1

2}, Renato D Lopes⁴, Anthony J Comerota⁵, Jawed Fareed³

Affiliations

¹ 1 Hospital e Maternidade Dr. Christovão da Gama, Santo André, São Paulo, Brazil.
² 2 Santa Casa de Sao Paulo School of Medical Sciences, São Paulo, Brazil.
³ 3 Loyola University Medical Center, IL, USA.
⁴ 4 Duke University Medical Center, Durham, NC, USA.
⁵ 5 Inova Heart and Vascular Institute, VA, USA.

Abstract

Direct oral anticoagulants (DOACs) are now widely used for the management of venous thromboembolism (VTE) that now includes cancer-associated thrombosis. This review summarizes recent data on VTE prophylaxis and treatment, new challenges, guidelines, and updates as well as the current place for DOACs on the emerging cancer-associated VTE management landscape.

Keywords: cancer; direct oral anticoagulants; venous thromboembolism.

Publication types

Review

MeSH terms

Administration, Oral
Anticoagulants / administration & dosage*
Anticoagulants / therapeutic use
Disease Management
Humans
Neoplasms / complications*
Thrombosis / drug therapy*
Venous Thromboembolism / prevention & control

Substances

Anticoagulants